Showing 3731-3740 of 5621 results for "".
- iHealthScreen Announces MHRA Certification and Registration for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-mhra-certification-and-registration-for-ipredict-automated-ai-system/2481997/iHealthScreen has received UK Medicines and Healthcare Products Regulatory Agency (MHRA) certification and registration for its iPredict AI Eye Screening System, which is used for the early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma. <
- Horus Pharma Strengthens Its International Expansionhttps://modernod.com/news/horus-pharma-strengthens-its-international-expansion/2481996/Horus Pharma, a France-based provider of preservative-free ophthalmology products, announced it is strengthening its international presence with eight distribution agreements covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland, and Bosnia. The deals take
- Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Boardhttps://modernod.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding N
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- OliX Pharmaceuticals Announces Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for AMDhttps://modernod.com/news/olix-pharmaceuticals-announces-positive-safety-data-and-preliminary-efficacy-effects-in-a-phase-1-trial-of-olx10212-for-age-related-macular-degeneration/2481988/OliX Pharmaceuticals announced positive results from a phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of age-related macular degeneration (AMD). The development of small interfering RNAs (siRNAs), like OLX10212, which showed efficacy in nonclinical models
- RetinAI Joins Ryan Initiative for Macular Research AMD Consortiumhttps://modernod.com/news/retinai-joins-ryan-initiative-for-macular-research-amd-consortium/2481987/RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.</
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe
- NORA Names New Executive and Advisory Board Membershttps://modernod.com/news/nora-names-new-executive-and-advisory-board-members/2481983/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the appointments of its new Executive and Advisory Board members. NORA is an interdisciplinary group of professionals dedicated to providing a complete ocular health evaluation and optimum visual rehabilitation educat
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Emily Chew, MD, Named NIH Distinguished Investigatorhttps://modernod.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/Emily, Chew, MD, has been promoted to the title of NIH Distinguished Investigator for her work as a care provider and clinical trialist. Dr. Chew directs National Eye Institute's Division of Epidemiology and Clinical Applications (DECA). An ophthalmologist, she specializes in c